Health Archive » October, 2008

Health - October, 2008

164 articles

• Why The Third Restatement Still Falls Short
• NJ Judge Refuses To Block Datascope Merger
• Court Affirms Noninfringement Of J&J Suture Patent
• Fed. Circ. Upholds Rejection Of Cancer Patent Claim
• Schering-Plough To Pay $31M In Mo. AWP Suit
• Jury Convicts Former National Century CEO Of Fraud
• Group Petitions FDA To Ban Avandia
• Faux-Blood Maker Says Med. Journal Article Libelous
• 3rd Circ. Affirms Fen-Phen Claim Denial
• Effects Of New Pa. Legislation On Health Care Costs
• Tyco Owes $58M In Needle Shield Patent Suit: Judge
• Business Method Patents Down But Not Out: Experts
• Paxil Judge Closes Door But Opens Window For GSK
• Mandatory Compliance With 'Voluntary' Codes
• Bifurcation Warranted In Lotrel Patent Spat: Judge
• Rejecting Expansive FCA False Certification Theory
• VNUS Ends Patent Fight Over Vein Laser Treatments
• AstraZeneca Sues Handa Again Over Seroquel XR
• Case Over Weight Loss Drug Gets A Little Thinner
• Slower Growth Forecast For US Drug Market In 2009
• Elan Faces Shareholder Suit Over Alzheimer's Drug
• Biogen Says Another Falls Ill After Taking MS Drug
• House Slams FDA In Run-Up To High Court Drug Case
• FDA Warns Bayer Over Aspirin-Supplement Combos
• Zydus Says Teva Patents Violate Antitrust Laws
• Cipro: A Road Map For Reverse Payment Litigation
• Holland & Knight Lands Top Health Care Litigator
• Medicis Hit With Securities Fraud Class Action
• Zyprexa MDL Judge Orders Conn. To Produce Records
• Novartis Adds Wyeth To Hemophilia Patent Hit List
• Teva Wins $100M Settlement From Broker Over ARS
• 2 Fen-Phen Plaintiffs' Attorneys Disbarred In Ky.
• NMT Jolts WL Gore Over Patented Heart Implant
• Backdating Suit Against Affymetrix Execs Continues
• Genentech's Rituxan, Others, Under Fire From Sanofi
• Shareholders Sue ImClone, Lilly Over Pending Merger
• Nigeria Case Settlement In Sight For Pfizer
• UnitedHealth Suit Filed Over Computer Booting Time
• Thoratec Issues Correction Of HeartMate II Pump
• State Failure-To-Warn Claims Found Preempted
• Business Method Inventors Await Decision In Bilski
• Watson Says Barr Infringes Patent For Oxytrol
• St. Jude Wields Patents Against Device Maker
• Kan. Sues Slew Of Drugmakers Over AWPs
• Bristol-Myers Shells Out $21M To Settle Orencia Suit
• UBS To Pay $100M To Settle HealthSouth Claims
• Squeaky Hip Implant Suit Against Stryker Tossed
• Plaintiff Says Clock Didn't Run Out On Ephedra Claim
• EU Rejects Cymbalta For Fibromyalgia Treatment
• Roche Sues Orchid Over Newest Boniva Patent
• Aerocrine Sues Apieron Over Asthma Monitor
• Bayer Prevails Again In Baycol MDL
• The Federal Preemption Battle Has Just Begun
• Judge Rules Against Recipients In Tissue-Theft MDL
• Otsuka Sues Apotex Again Over Generic Abilify
• No Medical Malpractice Sans Affidavit Of Merit: Court
• Final Settlement OK'd In Aetna Eating Disorders Suit
• Sanofi Pulls Obesity Drug Acomplia From EU Market
• Judge Orders Settlement Talks In Zyprexa MDL
• Jury Taps Wyeth For $3M In Fen-Phen Suit
• Report Questions Pfizer's Anti-Smoking Drug
• Endo Sues Barr Over Opana Patents
• FDA Data On Foreign Drugmakers Flawed: GAO
• Critics Applaud Top Whistleblower Counsel's Exit
• Takeda, Mylan Drop Claims In Diabetes Drug Suit
• Judge Hands Medtronic Win On Rapid-Exchange Bar
• KPMG Tossed From Merge Tech Suit, Again
• 1 In 4 Biotech Drugs Gets Safety Warning: Study
• Lilly Takes $1.4B Charge In Settlement Anticipation
• Fed. Circ. Upholds Preliminary Injunction On Biaxin XL
• $18.3M Fee Fund Gets Green Light In Medtronic MDL
• Steris Hasn't Solved Manufacturing Violations: FDA
• Cordis Hits Boston Scientific Over New Taxus Stent
• Tyco Loses JMOL Bid In Needle Shield Patent Suit
• 3rd Circ. Blocks Bid For Rehearing In Vioxx Suit
• Plaintiffs Lack Standing In Flonase Suit: GSK
• Feds Want Device Maker's Subpoena Suit Tossed
• Shareholders Launch Fraud Suit Against ArthroCare
• Liver Failure Suit Tackles Settlement Enforceability
• Leiner Health Gets Confirmation For Ch. 11 Exit
• Sens. Scrutinize Medical Industry Funding For Doctors
• Scientists Grade Agencies On Media Policies
• Surgery Tool Maker Sues Rival Over Drill Guide Patent
• Effects Of CMS Final Rules On Medicare, MIPPA
• Pfizer To Settle Celebrex, Bextra Suits For $894M
• FDA Adds Boxed Warning To Psoriasis Drug
• German Court Clears CoreValve In Patent Spat
• Lawyers Seek To Multiply Digitek Suits Against Actavis
• Okla. Sues McKesson Over Reported Drug Prices
• Merck Pushes To Sever Plaintiffs In Fosamax MDL
• Patient Care Ombudsman And Health Care Bankruptcy
• Court Shrinks Claims In Dow Corning Implant Scuffle
• Qui Tam Suit Over OxyContin A No-Go: Judge
• Judge Drops 37 More Plaintiffs From Baycol MDL
• Get Ready For Antitrust Trial, Judge Tells Sanofi
• Fed. Circ. Affirms Dismissal Of Reverse Payment Suit
• FDA Warns Boehringer About Misleading Mirapex Ads
• UK Court Denies Overcharge Damages In Cartel Suits
• Protective Order For Apotex Employees Mostly Denied
• Hi-Tech Loses Motion And Now Awaits FDA Decision
• FDA Warns CR Bard Over 'Adulterated' Med. Devices
• Baptist Health And Hospital-Physician Relations
• Lawmakers Probe Bayer Drug-Supplement Marketing
• Biolase, Diodem Settle Dispute Over Patent Deal
• NYC Can Withhold Docs In Insurance Antitrust Case
• FDA OKs Boston Scientific's New Taxus Stent
• AstraZeneca Sues Ivax, Teva Over Nexium Patent
• Employer-Sponsored Coverage Still Dropping: Study
• Fed. Circ. Upholds Preliminary Ban on Roche's Mircera
• Alcon Sues Synergetics Over Eye Laser Patent
• Wyeth Wins Philly Fen-Phen Case
• J&J Racks Up $69M In Ortho Evra Settlements: Report
• Biovail In Trouble With Shareholders Over Aplenzin
• Schulte Roth Seeks $1.5M In Fees For Quigley Ch. 11
• Prednisone Suit Proceeds Against Watson, Qualitest
• Chicago Hospital Seeks Buyer Due To Credit Crisis
• Invitrogen Sues Oxford Biomed Over Protein Patent
• Top Companies Singled Out For Emissions Reductions
• Managing The EU-US Discovery Conflict
• Ovarian Cancer Screening Test Not Approved: FDA
• Lawmakers Question FDA's Handling Of Actavis Recall
• Courts Can Defer To FDA On Diet Products: 11th Circ.
• Walgreen Seeks To Toss Wal-Vert Trademark Ruling
• Candela Skin Treatment Patent Case Sags
• DOJ Drops Motion Against Ranbaxy
• Court Thins Misconduct Claims In Syringe Patent War
• Suit Says Crestor Infringes Teva Patent
• Generic-Drug Companies And Federal Preemption
• Pfizer Accused Of Manipulating Epilepsy Drug Data
• Pfizer's Bextra Marketing 'Deceptive': Blue Cross
• Bayer's Yaz Ads 'Misleading:' FDA
• State Suit Not Preempted By Federal Vaccine Law: Ga.
• Drugmakers Promise Label Changes For Cold Meds
• 2 Wal-Mart Pharmacists May Be Eligible For Overtime
• Aventis Wants Sens.' Letter Excluded In Arava Case
• Lilly Settles Zyprexa State Claims In $62M Deal
• Judge Bends But Doesn't Break Knee Case
• AtheroGenics Converts Ch. 7 Bankruptcy Into Ch. 11
• Fed. Circ. Upholds Ruling For Aventis Over ALS Drug
• Govt. Steps Up To Plate In McKesson Kickback Case
• Supreme Court Won't Hear Appeal In Stent Dispute
• Judge Allows Ariad To Appeal Enbrel Case
• Kaiser To Pay $5.4M To Resolve Wage-And-Hour Suit
• Eli Lilly Picks Up ImClone For $6.5B
• Aetna Whistleblower Must Arbitrate Claims: 2nd Circ.
• Judge To Permanently Enjoin Roche's Mircera
• Analysis Of Walgreen-Longs Merger Misses Mark: CVS
• Representatives Slap FDA Over PR Contract Tactics
• Cardinal Health To Pay $34M To Settle Painkiller Case
• Cooley Godward Snags Displaced Heller Lawyers
• Court Bars Presuit Damages In Bone-Cleaning Case
• Medtronic, McDermott Ordered To Pay $4.4M In Fees
• Low Patent Allowance Hurts Innovation: Experts
• Doctors Urge FDA To Yank Children's Cold Meds
• FDA's View On Generic Drug Label Carve-Outs
• Court Reverses Verdict In Johns Hopkins Patent Case
• GSK Loses Bid To Toss Claims Over Paxil Suicide
• Congress Questions Medtronic On Kickbacks
• Court OKs $40M Paxil Deal With Third-Party Payors
• FDA's Challenge To Implied Outcomes Of ADHD Drugs
• 11th Circ. Prohibits CRA From Altering Health Benefits
• US, EU Set Off On 'Patent Prosecution Highway'
• Fla. AG Sues Merck To Recover Vioxx Payments
• J&J Unit Scores $1.2B Judgment In Stent Feud